High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition
Abstract
Abstract High-grade B-cell lymphoma with 11q aberration (HGBCL-11q) is a rare pediatric non-Hodgkin lymphoma. This study assessed outcome in 90 children with HGBCL-11q. With survival rates ≥95%, patients with HGBCL-11q and no predisposition are candidates for deescalated therapy in future prospective trials.
Article Details
Authors (21)
Leila Ronceray
1Department of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria
Minke H. W. Huibers
2Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Katrin Reutter
3Department of Pediatric Hematology and Oncology, Non-Hodgkin Lymphoma Berlin-Frankfurt-Münster Study Center, University Hospital Münster, Münster, Germany
Oussama Abla
2Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Mara Andrés
5Department of Pediatric Hematology and Oncology, University Hospital La Fe of Valencia, Valencia, Spain
Olga Balagué
6Hematopathology Section, Department of Pathology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
Monika Csóka
Gil Gilad
8Department of Pediatric Hematology and Oncology, Schneider Children’s Medical Center, Petah Tikva, Israel
Melanie M. Hagleitner
2Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Daiki Hori
10Department of Hematology and Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan
Lisa L. Hjalgrim
11Department of Pediatrics and Adolescent Medicine, University Hospital, Rigshospitalet, Copenhagen, Denmark
Janez Jazbec
12Division of Pediatric Hematology and Oncology, University Medical Center Ljubljana, Ljubljana, Slovenia
Wolfram Klapper
Atsuko Nakazawa
14Department of Clinical Research, Saitama Children’s Medical Center, Saitama, Japan
Jaime Verdú-Amorós
15Department of Pediatric Hematology and Oncology, Hospital Clínico Universitario, Biomedical Research Institute, Instituto de Investigación Sanitaria, Valencia, Valencia, Spain
Hannah von Mersi
1Department of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria
Wilhelm Wössmann
17Department of Pediatric Hematology and Oncology, Non-Hodgkin Lymphoma Berlin-Frankfurt-Münster Study Center, Medical Center Hamburg-Eppendorf, Hamburg, Germany
Ana C. Xavier
18Division of Hematology and Oncology, Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL
Birgit Burkhardt
3Department of Pediatric Hematology and Oncology, Non-Hodgkin Lymphoma Berlin-Frankfurt-Münster Study Center, University Hospital Münster, Münster, Germany
Itziar Salaverria
Andishe Attarbaschi